AstraZeneca has been successful at rolling out its long-acting complement C5 inhibitor Ultomiris in the uses approved for its predecessor Soliris – until now, that is. The drugmaker confirmed ...

Ultomiris was compared to an external placebo arm from the pivotal Soliris PREVENT trial in NMOSD, showing a 99% reduction in relapses at that time point, with zero seen in the active treatment group.

Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others.

The European Commission ((EC)) approved AstraZeneca's (AZN) Ultomiris to treat a rare central nervous system disorder. Read more here ...

Follow Add holdings Get top stock picks 1,338.00-19.00(-1.40%) At close: 5:29:46 PM GMT+2 Get top stock picks 1D 5D 1M 6M YTD 1Y 5Y All Key Events Mountain Advanced Chart Loading Chart for AZN.ST ...

Xencor, Inc. OverviewBiotechnology / Healthcare Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment ...